The FDA reports the following recent drug shortages and discontinuations:
- Spironolactone tablet (Aldactone, Pfizer) – 25 mg and 100 mg tablets discontinued; cardiovascular use.
- Doxercalciferol injection (Hectorol, Sanofi-Aventis) – all formulations discontinued; endocrinology use.
- Hydroxocobalamin injection – Cyanokit (5 g/250 mL), limited supply; Teva 1,000 mcg/mL vials unavailable until June 2026; used for vitamin B12 deficiency and cyanide poisoning.
- Carbamazepine ER capsules (Carbatrol, Takeda) – 100 mg, 200 mg, 300 mg strengths discontinued; for epilepsy and other neurologic conditions.
- Sodium acetate injection – ongoing shortages; availability varies by manufacturer (Fresenius Kabi, Hikma, Hospira/Pfizer, Milla).
- Morphine sulfate tablet (Upsher-Smith) – 15 mg and 30 mg discontinued; pain management.
- Mirikizumab-mrkz injection (Omvoh, Eli Lilly) – two 100 mg/1 mL formulations discontinued by Jan–April 2026; 200 mg/2 mL remains available; gastroenterology use.
- Acetaminophen; oxycodone hydrochloride tablet: (Endo Pharmaceuticals) – several strengths discontinued (325/2.5 mg, 5 mg, 7.5 mg, 10 mg); pain management.
Providers should check current availability before prescribing due to these changes.
Resource: 8 drugs in shortage